Viking Therapeutics: The Oral Program Launch Timing Leaves Little Room for Vagueness

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Viking typically reports earnings after market close, meaning Day 0 reflects anticipation before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Viking's post-earnings price action has been highly volatile, with an average absolute Day 0 move of 2.67% and Day +1 move of 5.54%. The Day +1 range averages 11.21%, indicating significant intraday swings as investors digest the results. The most dramatic reaction came in October 2024, when the stock surged 21.25% on Day +1 despite a modest -2.64% decline on Day 0. More recently, the February 2026 report saw a 6.80% Day +1 gain after a flat Day 0, while July 2026 produced minimal movement in both sessions. The pattern suggests that initial reactions are often muted, but follow-through can be substantial—particularly when results include unexpected clinical or strategic updates beyond the headline EPS figure. Investors should expect a wide trading range in the session following this release, with direction likely determined by management's commentary on the oral program and spending outlook rather than the EPS beat or miss alone.

Part 2.2: Options Market Expected Move

The options market is pricing a 6.63% expected move for the October 30 expiration, which is notably lower than Viking's average historical Day +1 move of 5.54% but well below the average Day +1 range of 11.21%. This suggests options traders are anticipating moderate volatility, though history shows the stock is capable of much larger swings—particularly when clinical or strategic updates accompany the earnings release.

Part 3: What Analysts Are Saying

Analysts remain overwhelmingly bullish on Viking Therapeutics despite the recent selloff. The consensus rating stands at 4.73 out of 5.00, with 19 Strong Buy ratings, 0 Moderate Buys, 3 Holds, and no Sell ratings among 22 analysts covering the stock. The average price target of $91.55 implies 268% upside from the current price of $24.89, with a high target of $125.00 and a low of $38.00.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 17 to 19 and the average recommendation ticking up from 4.70 to 4.73. This suggests that despite the stock's sharp decline, analysts view the recent weakness as a buying opportunity rather than a fundamental deterioration. The wide range between the high and low price targets ($125.00 vs. $38.00) reflects significant uncertainty around execution risk, particularly regarding the oral program's timeline and competitive positioning.

The consensus implies that if Viking can successfully execute on its dual-formulation strategy and demonstrate differentiation through maintenance dosing data, the stock has substantial room to recover. However, the three Hold ratings and the recent price target cut from Canaccord indicate that not all analysts are convinced the current valuation adequately reflects the risks of a crowded obesity market and rising capital requirements.

Part 4: Technical Picture

Viking Therapeutics enters earnings in a deeply oversold technical position. The Barchart Technical Opinion currently shows an 88% Sell signal, unchanged from last week but dramatically worse than the 8% Sell signal from a month ago. This sharp deterioration reflects the stock's 41% decline over the past month, which has pushed the price below all major moving averages.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates severe near-term downside momentum with no technical support
• Medium-term (100% Sell): Persistent sell signal confirms the intermediate-term trend has fully broken down
• Long-term (50% Sell): Moderate sell signal suggests the longer-term uptrend is now in question, though not completely reversed

Trend Characteristics: The signal strength is Strong and Strengthening, indicating the bearish momentum is accelerating rather than stabilizing—a cautionary setup heading into a high-stakes earnings release.

The stock is trading at $24.89, below all key moving averages: the 5-day ($25.14), 10-day ($25.55), 20-day ($27.30), 50-day ($31.00), 100-day ($32.81), and 200-day ($32.49). The cascading breakdown through these levels signals a complete loss of technical support, with the nearest resistance now at the 5-day moving average.

The technical setup is decidedly cautionary heading into earnings. With the stock below all moving averages and the Barchart Opinion showing maximum bearish intensity across short- and medium-term timeframes, any disappointment on the oral program or spending guidance could trigger further downside. However, the severity of the oversold condition also means a strong beat or compelling strategic update could spark a sharp reversal—particularly given the 268% upside implied by the analyst consensus. The key level to watch is the 20-day moving average at $27.30; a sustained move above that level would signal the beginning of technical repair, while failure to hold current levels could push the stock toward the $38.00 low analyst target.